Agios Pharmaceuticals (AGIO) Earning Somewhat Positive News Coverage, Analysis Finds

News coverage about Agios Pharmaceuticals (NASDAQ:AGIO) has been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 43.6049921736922 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Agios Pharmaceuticals (NASDAQ AGIO) opened at 71.12 on Tuesday. The stock’s 50 day moving average is $66.25 and its 200 day moving average is $56.71. The stock’s market capitalization is $3.44 billion. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.47) earnings per share. Analysts forecast that Agios Pharmaceuticals will post ($7.08) EPS for the current year.

Several research analysts have issued reports on AGIO shares. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reiterated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $75.20.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2017/10/17/agios-pharmaceuticals-agio-earning-somewhat-positive-news-coverage-analysis-finds.html.

In other news, CEO David P. Schenkein sold 27,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00. Following the sale, the director now directly owns 86,394 shares of the company’s stock, valued at approximately $5,656,215.18. The disclosure for this sale can be found here. Insiders have sold 228,408 shares of company stock valued at $14,976,478 in the last three months. 10.55% of the stock is owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Agios Pharmaceuticals (NASDAQ AGIO) opened at 71.12 on Tuesday. The stock’s 50 day moving average is $66.25 and its 200 day moving average is $56.71. The stock’s market capitalization is $3.44 billion. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.47) earnings per share. Analysts forecast that Agios Pharmaceuticals will post ($7.08) EPS for the current year.

Several research analysts have issued reports on AGIO shares. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reiterated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $75.20.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2017/10/17/agios-pharmaceuticals-agio-earning-somewhat-positive-news-coverage-analysis-finds.html.

In other news, CEO David P. Schenkein sold 27,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00. Following the sale, the director now directly owns 86,394 shares of the company’s stock, valued at approximately $5,656,215.18. The disclosure for this sale can be found here. Insiders have sold 228,408 shares of company stock valued at $14,976,478 in the last three months. 10.55% of the stock is owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.